<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03883334</url>
  </required_header>
  <id_info>
    <org_study_id>HUBI - 12522</org_study_id>
    <nct_id>NCT03883334</nct_id>
  </id_info>
  <brief_title>Isoprinosine in HIV Patients With Viral Load &gt; 50 y &lt; 200 Copies/mL</brief_title>
  <official_title>Efecto de la Isoprinosina en Pacientes Con infección Por VIH y Carga Viral Entre &gt; 50 y &lt; 200 Copias/mL de la Unidad de atención de PVV Del Hospital Enrique Garcés en Quito, Ecuador Durante el año 2019.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidad San Francisco de Quito</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidad San Francisco de Quito</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Virological failure is a complication of treatment in patients with HIV, and it can be as
      high as 42% to first line treatment or around 18% in second line treatment. The reasons
      behind this phenomenon are several, including adherence to treatment (self-patient) or those
      related to the drugs (kinetics, interactions) and the virus itself (resistance patterns).
      People living with HIV needs treatment for all their lives, another factor to facilitate
      virus resistance and poor adherence to treatment. For that reason, it is necessary to look
      for additional therapeutic options to minimize this problem, and the use of immunomodulatory
      drugs is an interesting topic now. Among those drugs, isoprinosine hs been reported not only
      improve the immune response, it also has the capability to inhibit the replication of RNA
      virus. Then, we propose an open label clinical trial to evaluate the effect of isoprinosine
      in HIV patients with a virological load between 50 and 200 copies/ml.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 28, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Viral load</measure>
    <time_frame>Change from Baseline viral load at 3 months</time_frame>
    <description>Number of viral copies/mL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CD4+ count</measure>
    <time_frame>Change from Baseline CD4+ count at 3 months</time_frame>
    <description>Number of CD4+ cells</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Immunomodulator group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metisoprinol 1 gr every 8 h per ten days during three months plus the combine antiretroviral therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>combine antiretroviral therapy only</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metisoprinol</intervention_name>
    <description>Immunodulator</description>
    <arm_group_label>Immunomodulator group</arm_group_label>
    <other_name>Isoprinosine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Older than 18 years old.

          -  Patients with a viral load (RNA of VIH) between &gt; 50 and &lt; 200 copies/mL after 24
             weeks of antiviral therapy or after scheme change.

          -  Informed consent signature

        Exclusion Criteria:

          -  Younger than 18 years old.

          -  No virologic failure or RNA of VIH &gt; 200 copies/mL.

          -  Presence of a serious opportunistic infection.

          -  Renal failure (including litiasis) or presence of gout.

          -  Pregnancy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Enrique Teran, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Universidad San Francisco de Quito</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Enrique Garces</name>
      <address>
        <city>Quito</city>
        <zip>170901</zip>
        <country>Ecuador</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Ecuador</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>February 7, 2019</study_first_submitted>
  <study_first_submitted_qc>March 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 20, 2019</study_first_posted>
  <last_update_submitted>December 19, 2019</last_update_submitted>
  <last_update_submitted_qc>December 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidad San Francisco de Quito</investigator_affiliation>
    <investigator_full_name>Enrique Teran</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inosine Pranobex</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

